The American Association of Pharmaceutical Scientists (AAPS) has officially announced the appointment of Dr. Patrick J. Sinko as its new…
Read More
The FDA plans its third rare disease policy change in just over a year
On October 14, 2026, the U.S. Food and Drug Administration (FDA) formally unveiled the "Rare Disease Framework Initiative," a comprehensive…
Read More
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
Roche has solidified its strategic pivot toward the Chinese biotechnology sector by entering into a landmark $400 million partnership with…
Read More
Tufts model estimates 82x ROI and up to $21 million in value from Medable AI agent
The integration of artificial intelligence into the pharmaceutical industry has reached a critical inflection point, as a new collaborative analysis…
Read More
AAPS PharmSci 360 Offers Fresh Insights for Industry Scientists
The pharmaceutical landscape is currently undergoing a period of rapid transformation, driven by the integration of artificial intelligence, complex biologics,…
Read More
As the dream of the autonomous clinical trial dawns, agent supervision is today’s human job
The landscape of clinical research is currently undergoing a structural transformation characterized by an unprecedented surge in data complexity. In…
Read More
Pharma tariffs reach smaller drugmakers as industry warns of R&D pressure
The landscape of American pharmaceutical manufacturing is undergoing a seismic shift as the U.S. government implements a aggressive trade policy…
Read More
AbbVie’s Maviret cured 96% of HCV trial participants. The real world is more complicated.
The global landscape of hepatitis C virus (HCV) management has shifted significantly in the past decade, moving from a era…
Read More
AAPS names Patrick Sinko chief science officer
The American Association of Pharmaceutical Scientists (AAPS), a global non-profit organization representing more than 7,000 members, has officially appointed Dr.…
Read More
The oral exposure challenge in PROTACs: What drug developers need to solve early
Proteolysis Targeting Chimera (PROTAC) technology has transitioned from a theoretical breakthrough in chemical biology to a validated clinical reality. In…
Read More
